http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#Head http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#assertion http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#provenance http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#pubinfo http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#assertion http://purl.obolibrary.org/obo/DOID_2355 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_2355 http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00727 http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#association http://www.w3.org/2000/01/rdf-schema#label "* Use of phosphodiesterase type 5 (PDE-5) inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil, or soluble guanylate cyclase (sGC) stimulators. (4.1, 7.1) * Severe anemia (4.2) * Increased intracranial pressure (4.3) * Hypersensitivity to nitroglycerin sublingual tablets or to other nitrates or nitrites or any excipient (4.4) * Circulatory failure and shock (4.5) Do not use nitroglycerin sublingual tablets in patients who are taking PDE-5 Inhibitors, such as avanafil, sildenafil, tadalafil, vardenafil hydrochloride. Concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see Drug Interactions ( 7.1 Do not use nitroglycerin sublingual tablets in patients who are taking the soluble guanylate cyclase stimulators, such as riociguat. Concomitant use can cause hypotension. Nitroglycerin sublingual tablets are contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). Nitroglycerin sublingual tablets may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e.g., cerebral hemorrhage or traumatic brain injury). Nitroglycerin sublingual tablets are contraindicated in patients who are allergic to nitroglycerin, other nitrates or nitrites or any excipient. Nitroglycerin sublingual tablets are contraindicated in patients with acute circulatory failure or shock." http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#association https://w3id.org/biolink/vocab/relation https://schema.org/MedicalContraindication https://identifiers.org/drugbank:DB00727 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#provenance http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#pubinfo http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#sig http://purl.org/nanopub/x/hasSignature BCGlV4oQp3JkI8KCv6WD6UYS32uTU2nPWr5I6Y9l/KJs28zucIP5dhEAEnYVgDAFHjF7YUzuZqLIRzhUDxNyfBFW2Yy27tDM49Vl3rT4me5yNu9/JZlqnCP9pzz5aV9roQXPzO47SaXxsE61RBiH03ylYPaoBlJCy+7efARtJwQ= http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw http://purl.org/dc/terms/created 2021-08-23T18:45:39.569+02:00 http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY